Eloxx Pharmaceuticals, Inc. (ELOX): Nasdaq/NYSE listing notice — Eloxx receives Nasdaq delisting notice for failing to maintain $35M market value

Eloxx Pharmaceuticals, Inc.

Received delisting notice on April 11, 2023, for non-compliance with Nasdaq's $35M minimum market value requirement.
Company failed to regain compliance during the 180-day grace period that ended April 10, 2023.
Trading will be suspended on April 20, 2023, unless company requests a hearing by April 18, 2023.
Company intends to appeal; a hearing request will stay the suspension pending Panel decision.
There is no assurance the appeal will succeed or that continued listing will be granted.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Eloxx Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

April 11, 2023, Eloxx Pharmaceuticals, Inc. (the “ Company ”) received a determination letter (the “ Letter ”) from the staff (the “ Staff ”) of the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that the Company has not regained compliance with Listing Rule 5550(b)(2) (the “ Minimum Market Value Requirement ”), requiring the Company to maintain a Market Value of Listed Securities of a minimum of $35 million, during the 180-day grace period previously granted to the Company. As previously disclosed, the Company was initially notified by the Staff on Octob

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-045573

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.